Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

Quantifying Lipid Components in Messenger RNA–Lipid Nanoparticle Formulations: A Review of Liquid Chromatography–Mass Spectrometry Methods

Academic source · Physchem

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What the paper reports

This review compares liquid chromatography and mass spectrometry strategies for quantifying ionizable lipids, PEG lipids, helper phospholipids, cholesterol, and degradation products in mRNA-LNP formulations. It considers sensitivity, linearity, run time, matrix effects, and stability-indicating measurements. The comparison supports method selection rather than demonstrating a single validated release assay applicable to every formulation.

Why this paper is included

Connects lipid composition with degradation monitoring; developers must establish formulation-specific suitability, recovery, and validation rather than relying on a generic lipid assay.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP

Related updates

Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNPAsk AI ↗
Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

mRNA / LNP Clinical Pharmacology & Model-Informed DevelopmentAsk AI ↗
Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNPAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗